Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.08 CAD | 0.00% | 0.00% | +23.08% |
03-27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% | MT |
03-27 | MediPharm Labs Narrows Q4 Loss, Revenue Grows | MT |
Sales 2024 * | 43.06M 31.45M 2.52B | Sales 2025 * | 58.43M 42.66M 3.42B | Capitalization | 32.32M 23.6M 1.89B |
---|---|---|---|---|---|
Net income 2024 * | -7M -5.11M -410M | Net income 2025 * | -1M -730K -58.62M | EV / Sales 2024 * | 0.75 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.55 x |
P/E ratio 2024 * |
-5.33
x | P/E ratio 2025 * |
-
| Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.52% |
Latest transcript on MediPharm Labs Corp.
1 month | -11.11% | ||
3 months | +23.08% | ||
6 months | +6.67% | ||
Current year | +23.08% |
Managers | Title | Age | Since |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 19/04/22 |
Greg Hunter
DFI | Director of Finance/CFO | - | 07/02/21 |
Keith Strachan
PSD | President | - | 30/09/18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 31/03/23 |
David Pidduck
CEO | Chief Executive Officer | - | 19/04/22 |
Shelley Martin
BRD | Director/Board Member | - | 21/06/20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.83% | 35 M€ | +18.97% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 0.08 | 0.00% | 228,800 |
25/04/24 | 0.08 | 0.00% | 51,440 |
24/04/24 | 0.08 | +6.67% | 440,300 |
23/04/24 | 0.075 | 0.00% | 118,919 |
22/04/24 | 0.075 | -6.25% | 280,373 |
Delayed Quote Toronto S.E., April 26, 2024 at 06:56 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.08% | 23.61M | |
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
+2.14% | 3.1B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B |
- Stock Market
- Equities
- LABS Stock